Who
Helen Susan Kim
Director and 10% owner
Company insider
Files Form 4 as: Director and 10% owner, Aktis Oncology; Director, Prothena Corporation; Director, Applied Molecular Transport; Director, Assembly Biosciences; Director, Exicure; EVP, Business Development, Kite Pharma; Director, Sunesis Pharmaceuticals; Director, ImmunoCellular Therapeutics.
In numbers
- Trades disclosed
- 148
- Buys
- 2
- Sells
- 17
- Bought
- $30.1M
- Sold
- $29.4M
- Companies
- 9
- Companies where not an officer
- 7
- First trade
- 3 Jan 2008
- Last trade
- 12 Jan 2026
- Last filed
- 12 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Jan 2026filed 12 Jan 2026 | AKTS Aktis OncologyBiotechnology | SEC FORM 4 Code C | —4,859,370 | filing |
| 12 Jan 2026filed 12 Jan 2026 | AKTS Aktis OncologyBiotechnology | SEC FORM 4 Bought | $14.6M812,455 at $18.00 | filing |
| 12 Jan 2026filed 12 Jan 2026 | AKTS Aktis OncologyBiotechnology | SEC FORM 4 Code C | —134,842 | filing |
| 12 Jan 2026filed 12 Jan 2026 | AKTS Aktis Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code C | —14,838,250 at $0.00 | filing |
| 12 Jan 2026filed 12 Jan 2026 | AKTS Aktis Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code C | —411,750 at $0.00 | filing |
| 12 Jan 2026filed 12 Jan 2026 | AKTS Aktis Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code C | —3,648,750 at $0.00 | filing |
| 12 Jan 2026filed 12 Jan 2026 | AKTS Aktis Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code C | —101,250 at $0.00 | filing |
| 12 Jan 2026filed 12 Jan 2026 | AKTS Aktis OncologyBiotechnology | SEC FORM 4 Bought | $406K22,545 at $18.00 | filing |
| 12 Jan 2026filed 12 Jan 2026 | AKTS Aktis Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code C | —14,838,250 at $0.00 | filing |
| 12 Jan 2026filed 12 Jan 2026 | AKTS Aktis Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code C | —411,750 at $0.00 | filing |
| 12 Jan 2026filed 12 Jan 2026 | AKTS Aktis Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code C | —3,648,750 at $0.00 | filing |
| 12 Jan 2026filed 12 Jan 2026 | AKTS Aktis Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code C | —101,250 at $0.00 | filing |
| 12 Jan 2026filed 12 Jan 2026 | AKTS Aktis OncologyBiotechnology | SEC FORM 4 Code C | —4,859,370 | filing |
| 12 Jan 2026filed 12 Jan 2026 | AKTS Aktis OncologyBiotechnology | SEC FORM 4 Bought | $14.6M812,455 at $18.00 | filing |
| 12 Jan 2026filed 12 Jan 2026 | AKTS Aktis OncologyBiotechnology | SEC FORM 4 Code C | —134,842 | filing |
| 12 Jan 2026filed 12 Jan 2026 | AKTS Aktis OncologyBiotechnology | SEC FORM 4 Bought | $406K22,545 at $18.00 | filing |
| 14 May 2025filed 16 May 2025 | PRTA Prothena Corporationoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,183 at $0.00 | filing |
| 15 May 2024filed 17 May 2024 | PRTA Prothena Corporationoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 17 May 2023filed 19 May 2023 | PRTA Prothena Corporationoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 31 Aug 2022filed 2 Sep 2022 | PRTA Prothena Corporationoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
News
PTC Therapeutics (NASDAQ:PTCT) & Aktis Oncology (NASDAQ:AKTS) Head to Head ContrastAKTS · dailypolitical.com · 19 Oct 2026
0 headlines in the last 90 days name Helen Susan Kim; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.